A Phase 2 Study of Alisertib (MLN8237) in Recurrent or Persistent Uterine Leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group Study 0231D

OBJECTIVE: This two-stage Phase II study assessed the activity of single agent alisertib in patients with recurrent/persistent uterine leiomyosarcoma (uLMS). METHODS: Eligibility criteria included histologically-confirmed, recurrent or persistent uLMS, age ≥18, 1-2 prior cytotoxic regimens, and RECI...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Gynecol Oncol
Autori principali: Hyman, David M, Sill, Michael W, Lankes, Heather A, Piekarz, Richard, Shahin, Mark S, Ridgway, Mildred R, Backes, Floor, Tenney, Meaghen E, Mathews, Cara A., Hoffman, James S, Aghajanian, Carol, Hensley, Martee L
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2016
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5260802/
https://ncbi.nlm.nih.gov/pubmed/28094040
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2016.10.036
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi